Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARD | Q03181 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | LPAR3 | Q9UBY5 | 3/20 | 0.32 |
| ▸ | LPAR1 | Q92633 | 2/20 | 0.32 |
| ▸ | LPAR2 | Q9HBW0 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2992408 | 0.88 | PPARD (0.36) | PPARDALDH1A1LPAR3LPAR1LPAR2 | |
| SCHEMBL17331123 | 0.83 | FFAR3 (0.42) | PPARDALDH1A1MEN1KMT2A | |
| SCHEMBL2991834 | 0.83 | PPARD (0.58) | PPARDALDH1A1 | |
| SCHEMBL17860960 | 0.82 | PPARD (0.41) | PPARDALDH1A1MEN1KMT2ALPAR3 | |
| SCHEMBL9819300 | 0.82 | PPARD (0.38) | PPARDMEN1KMT2ALPAR3LPAR1 | |
| SCHEMBL17860892 | 0.82 | PPARD (0.38) | PPARDMEN1KMT2ALPAR3LPAR1 | |
| SCHEMBL2240315 | 0.80 | DGKA (0.42) | PPARDALDH1A1LPAR3LPAR1LPAR2 | |
| SCHEMBL15951683 | 0.80 | TSHR (0.44) | PPARDALDH1A1MEN1KMT2A | |
| SCHEMBL10757799 | 0.79 | LMNA (0.36) | PPARDALDH1A1MEN1KMT2ALPAR1 | |
| SCHEMBL28916160 | 0.79 | HDAC2 (0.48) | PPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771394-B2 | Antimicrobial polymyxins for treatment of bacterial infections | MICURX PHARMACEUTICALS, INC. (KY) | 2017-09-26 | — | — | US | disclosed |
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | MICURX PHARMACEUTICALS, INC. | 2016-06-30 | — | — | US | disclosed |
| US-8962192-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2015-02-24 | — | — | US | disclosed |
| US-8574757-B2 | Nonaqueous electrolytic solution and nonaqueous electrolyte battery | MITSUBISHI CHEMICAL CORPORATION (JP) | 2013-11-05 | — | — | US | disclosed |
| US-20120264011-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20100035147-A1 | NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTE BATTERY | MITSUBISHI CHEMICAL CORPORATION (JP) | 2010-02-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160185823-A1 | ANTIMICROBIAL POLYMYXINS FOR TREATMENT OF BACTERIAL INFECTIONS | VIP, AQP1, PEF1 | PPARD 1269/4885ALDH1A1 4807/4885MEN1 2965/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.